ENTRADA THERAPEUTICS, INC. (TRDA) Spending and interest coverage
- R&D / revenue · 12 months: Value 3003.44%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 413.32%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 3003.44% | Research and development expense / revenue. Period ending 2026-06-30. $140.74M ÷ $4.69M × 100 ≈ 3003.44% |
| Stock-based compensation / revenue · 12 months | 413.32% | Share-based compensation / revenue. Period ending 2026-06-30. $19.37M ÷ $4.69M × 100 ≈ 413.32% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 140.74M USD | Research and Development Expense |
| Revenue | 4.69M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 19.37M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -176.53M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $140.74M | $4.69M | $19.37M | $-176.53M | (m) | 3003.44% | 413.32% | (m) | (m) |
| 2026-03-31 | $143.25M | $5.74M | $19.27M | $-178.41M | (m) | 2496.50% | 335.76% | (m) | (m) |
| 2025-12-31 | $142.27M | $25.42M | $19.61M | $-157.90M | (m) | 559.65% | 77.14% | (m) | (m) |
| 2025-09-30 | $141.72M | $61.52M | $19.95M | $-121.56M | (m) | 230.36% | 32.43% | (m) | (m) |
| 2025-06-30 | $134.61M | $79.48M | $19.70M | $-96.16M | (m) | 169.38% | 24.78% | (m) | (m) |
| 2025-03-31 | $128.77M | $172.22M | $19.27M | $4.11M | (m) | 74.77% | 11.19% | (m) | (m) |
| 2024-12-31 | $125.31M | $210.78M | $17.91M | $47.01M | (m) | 59.45% | 8.50% | (m) | (m) |
| 2024-09-30 | $120.19M | $215.23M | $17.06M | $57.78M | (m) | 55.84% | 7.92% | (m) | (m) |
| 2024-06-30 | $111.13M | $239.40M | $15.59M | $93.45M | (m) | 46.42% | 6.51% | (m) | (m) |
| 2024-03-31 | $105.39M | $162.87M | $14.09M | $23.73M | (m) | 64.71% | 8.65% | (m) | (m) |
| 2023-12-31 | $99.88M | $129.01M | $13.11M | $-3.16M | (m) | 77.42% | 10.16% | (m) | (m) |
| 2023-09-30 | $87.28M | (m) | $12.15M | $-33.65M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $84.05M | (m) | $11.46M | $-73.59M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $73.99M | (m) | $10.86M | $-80.88M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $66.61M | (m) | $9.89M | $-97.25M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $63.29M | (m) | $8.47M | $-90.13M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $54.84M | (m) | $6.34M | $-78.56M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $45.42M | (m) | $4.16M | $-64.89M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $35.93M | (m) | $2.53M | $-51.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $21.10M | (m) | $325.00K | $-26.67M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |